Has the survival of patients with glioblastoma changed over the years?

被引:53
作者
deSouza, R. M. [1 ]
Shaweis, H. [1 ]
Han, C. [2 ]
Sivasubramiam, V. [1 ]
Brazil, L. [3 ]
Beaney, R. [3 ]
Sadler, G. [4 ]
Al-Sarraj, S. [5 ]
Hampton, T. [6 ]
Logan, J. [1 ]
Hurwitz, V. [1 ]
Bhangoo, R. [1 ]
Gullan, R. [1 ]
Ashkan, K. [1 ]
机构
[1] Kings Coll Hosp London, Dept Neurosurg, Denmark Hill, London SE5 9RS, England
[2] Univ Oxford, Canc & Haematol Ctr, Med Stat, Dept Oncol,Churchill Hosp, Oxford OX3 7LE, England
[3] Guys & St Thomas NHS Fdn Trust, Dept Clin Oncol, London SE1 9RT, England
[4] Maidstone & Tunbridge Wells NHS Trust, Kent Oncol Ctr, Dept Clin Oncol, Hermitage Lane, Maidstone ME16 9QQ, Kent, England
[5] Kings Coll Hosp London, Dept Neuropathol, Denmark Hill, London SE5 9RS, England
[6] Kings Coll Hosp London, Dept Neuroradiol, Denmark Hill, London SE5 9RS, England
关键词
glioblastoma; survival; time; neuro-oncology; POPULATION-BASED REGISTRY; RANDOMIZED PHASE-III; MALIGNANT GLIOMA; RECURRENT GLIOBLASTOMA; ADJUVANT TEMOZOLOMIDE; CLINICAL-TRIAL; SURGERY; RADIOTHERAPY; RESECTION; MGMT;
D O I
10.1038/bjc.2015.421
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Over the last decade, the approach to the management of brain tumours and the understanding of glioblastoma tumour biology has advanced and a number of therapeutic interventions have evolved, some of which have shown statistically significant effects on overall survival (OS) and progression-free survival in glioblastoma. The aim of this study is to compare survival in glioblastoma patients over a 10-year period (1999-2000 and 2009-2010). Methods: A retrospective cohort study was performed. Identification of all histologically confirmed glioblastoma in a single centre in years 1999, 2000, 2009 and 2010, and production of survival analysis comparing 1999-2000 and 2009-2010 were achieved. Results: A total of 317 patients were included in the analysis (133 in year 1999-2000, and 184 in year 2009-2010). Cox regression analysis showed that the survival was significantly longer in patients in years 2009-2010 than those in 1999-2000 at P<0.001 with HR = 0.56, confidence interval (CI) (0.45-0.71). The 1- and 3-year survival rates were 20.7% and 4.4%, respectively, for patients in 1999-2000, improving to 40.0% and 10.3%, respectively, for patients in 2009-2010. The comparisons between the two groups in survival at 1, 2 and 3 years are all statistically significant at P<0.001, respectively. The median OS was 0.36 and 0.74 in 1999-2000 and 2009-2010 groups, respectively. Conclusions: Over this period, OS from glioblastoma has increased significantly in our unit. We believe this is due to the institution of evidence-based surgical and oncological strategies practised in a multidisciplinary setting.
引用
收藏
页码:146 / 150
页数:5
相关论文
共 40 条
[1]  
[Anonymous], COCHRANE DATABASE SY
[2]   Brain tumors in Sweden: Data from a population-based registry 1999-2012 [J].
Asklund, Thomas ;
Malmstrom, Annika ;
Bergqvist, Michael ;
Bjor, Ove ;
Henriksson, Roger .
ACTA ONCOLOGICA, 2015, 54 (03) :377-384
[3]   Considerable improvement in survival for patients aged 60-84 years with high grade malignant gliomas - Data from the Swedish Brain Tumour Population-based Registry [J].
Asklund, Thomas ;
Malmstrom, Annika ;
Bjor, Ove ;
Blomquist, Erik ;
Henriksson, Roger .
ACTA ONCOLOGICA, 2013, 52 (05) :1043-1046
[4]   Heterogeneity Maintenance in Glioblastoma: A Social Network [J].
Bonavia, Rudy ;
Inda, Maria-del-Mar ;
Cavenee, Webster K. ;
Furnari, Frank B. .
CANCER RESEARCH, 2011, 71 (12) :4055-4060
[5]   Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [J].
Esteller, M ;
Garcia-Foncillas, J ;
Andion, E ;
Goodman, SN ;
Hidalgo, OF ;
Vanaclocha, V ;
Baylin, SB ;
Herman, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (19) :1350-1354
[6]   Evaluating the prognostic factors effective on the outcome of patients with glioblastoma multiformis: does maximal resection of the tumor lengthen the median survival? [J].
Faramarz-Allandini ;
Amirjamshidi, Abbass ;
Reza-Zarei, Mohammad ;
Abdollahi, Morteza .
WORLD NEUROSURGERY, 2010, 73 (02) :128-134
[7]   Clinical trial participation and outcome for patients with glioblastoma: Multivariate analysis from a comprehensive dataset [J].
Field, Kathryn M. ;
Drummond, Katharine J. ;
Yilmaz, Merve ;
Tacey, Mark ;
Compston, Daniel ;
Gibbs, Peter ;
Rosenthal, Mark A. .
JOURNAL OF CLINICAL NEUROSCIENCE, 2013, 20 (06) :783-789
[8]   Comparison of 18F-FET PET and 5-ALA fluorescence in cerebral gliomas [J].
Floeth, Frank Willi ;
Sabel, Michael ;
Ewelt, Christian ;
Stummer, Walter ;
Felsberg, Jorg ;
Reifenberger, Guido ;
Steiger, Hans Jakob ;
Stoffels, Gabriele ;
Coenen, Heinz Hubert ;
Langen, Karl-Josef .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (04) :731-741
[9]   Gliobastoma multiforme and the epidermal growth factor receptor [J].
Friedman, HS ;
Bigner, DD .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (19) :1997-1999
[10]   Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial [J].
Gilbert, Mark R. ;
Wang, Meihua ;
Aldape, Kenneth D. ;
Stupp, Roger ;
Hegi, Monika E. ;
Jaeckle, Kurt A. ;
Armstrong, Terri S. ;
Wefel, Jeffrey S. ;
Won, Minhee ;
Blumenthal, Deborah T. ;
Mahajan, Anita ;
Schultz, Christopher J. ;
Erridge, Sara ;
Baumert, Brigitta ;
Hopkins, Kristen I. ;
Tzuk-Shina, Tzahala ;
Brown, Paul D. ;
Chakravarti, Arnab ;
Curran, Walter J., Jr. ;
Mehta, Minesh P. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4085-+